title: Reduction of Inflammatory and Noninflammatory Lesions with Topical Tyrothricin 0.1% in the Treatment of Mild to Severe Acne Papulopustulosa: A Randomized Controlled Clinical Trial.
abstract: OBJECTIVE
  Antibiotic-induced drug resistance requires new approaches in topical acne treatment. Tyrothricin is known to produce no resistance. In this study, it was tested for the first time in topical acne treatment. The efficacy and tolerability of topical tyrothricin 0.1% was evaluated.
  
  
  METHODS
  A randomized, active comparator-controlled, exploratory, observer-blind clinical study was conducted in 24 patients with acne papulopustulosa. Randomization on a split-face was either tyrothricin versus clindamycin + benzoyl peroxide (BPO) (n = 12) or tyrothricin versus BPO 5% (n = 12). The main outcome was change in inflammatory and noninflammatory lesion counts.
  
  
  RESULTS
  The mean differences in inflammatory lesion counts from baseline were -12.3 (95% CI: -20.5 to -4.1) in clindamycin + BPO, -10.2 (95% CI: -15.3 to -5.0) in BPO 5%, and -7.7 (95% CI: -11.7 to -3.7) in tyrothricin. Tyrothricin reduced noninflammatory lesions (mean difference: -6.5 (95% CI: -11.6 to -1.4) and caused less product-related adverse events (n = 31) compared to BPO (n = 37) and clindamycin + BPO (n = 20).
  
  
  CONCLUSIONS
  The results indicate that tyrothricin might be a candidate for treating acne and it seems to be more tolerable than both comparator treatments.
authors.affiliation: Clinical Research Center for Hair and Skin Science, Department of Dermatology and Allergy, Charitx00E9; - Universitx00E4;tsmedizin Berlin, Berlin, Germany.
authors.forename: Claudia
authors.initials: C
authors.lastname: Richter
authors.forename: Carina
authors.initials: C
authors.lastname: Trojahn
authors.forename: Kathrin
authors.initials: K
authors.lastname: Hillmann
authors.forename: Gabor
authors.initials: G
authors.lastname: Dobos
authors.forename: Andrea
authors.initials: A
authors.lastname: Stroux
authors.forename: Jan
authors.initials: J
authors.lastname: Kottner
authors.forename: Ulrike
authors.initials: U
authors.lastname: Blume-Peytavi
mesh_terms: D000152:Acne Vulgaris / Q000188:drug therapy*; D000287:Administration, Topical; D000293:Adolescent; D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D001585:Benzoyl Peroxide / Q000627:therapeutic use; D002981:Clindamycin / Q000627:therapeutic use; D003879:Dermatologic Agents / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D016037:Single-Blind Method; D016896:Treatment Outcome; D014449:Tyrothricin / Q000627:therapeutic use*; D055815:Young Adult
chemical_list: D000900:Anti-Bacterial Agents; D000893:Anti-Inflammatory Agents; D003879:Dermatologic Agents; D014449:Tyrothricin; D002981:Clindamycin; D001585:Benzoyl Peroxide